Goldman Sachs downgrades Moderna amid uncertainty
- Goldman Sachs downgraded Moderna from buy to neutral citing limited visibility.
- Analysts expect continued strength for Apple and Walmart heading into earnings.
- The overall market shows a mix of bullish and cautious sentiments as earnings reports approach.
As of January 29, 2025, various major analysts have been actively providing insights regarding significant stocks ahead of earnings reports. Goldman Sachs has decided to downgrade Moderna from a buy to a neutral rating. This action is prompted by the firm’s assertion of limited visibility regarding the company's future performance. The analysts perceive that recent weaknesses within the biotech sector present a potentially attractive buying opportunity for stocks such as Nvidia, ALAB, and ARM. Furthermore, Evercore ISI has reiterated a positive outlook for Apple, predicting steady growth ahead of its quarterly earnings report, thanks to strong contributions from its services and wearables segments. In an optimistic note, Goldman Sachs remains bullish on Walmart, anticipating the retail giant will continue to achieve robust earnings growth through 2025, driven by its solid market position and value offerings. Meanwhile, Barclays maintains an overweight position on Microsoft, despite the company's stated Azure capacity constraints, with expectations for initial guidance regarding the March quarter. The landscape continues to shift as Mizuho upgrades Coinbase, citing anticipated further bitcoin adoption, while Guggenheim maintains a sell rating on Tesla as it heads towards its earnings report. Overall, the markets are bracing for a series of corporate earnings announcements which could significantly impact stock valuations across various sectors.